In fact, close to 19% of HNSCC tumors harbor inactivating mutations in Notch1, making it the second most commonly mutated gene after TP53. However, other recent reports demonstrate an overexpression of Notch pathway components in HNSCC tumors suggesting oncogenic properties of the pathway21–25. This evidence concerns the gene NOTCH1 and head and neck squamous cell carcinoma.